Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial

European Psychiatry

Volumn 30, Issue 8, 2015, Pages 975-982

  Conus, P ^a,b   Berk, M ^b,c,d   Cotton, S M ^b   Kader, L ^b   Macneil, C ^b   Hasty, M K ^b   Hallam, K ^b   Lambert, M ^e   Murphy, B P ^f   McGorry, P D ^b  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f MONASH UNIVERSITY   (Australia)

Author keywords

Antipsychotic treatment; Bipolar disorder; First episode; Mania; Psychosis

Indexed keywords

CHLORPROMAZINE; LITHIUM; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ACCOMMODATION DISORDER; ADD ON THERAPY; ADOLESCENT; ADULT; ADVERSE OUTCOME; ARTICLE; ASTHENIA; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; LASSITUDE; MAJOR CLINICAL STUDY; MALE; MANIA; MEDICAL ETHICS; MEDICATION COMPLIANCE; MEMORY DISORDER; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SALIVATION DISORDER; SEDATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SURVIVAL RATE; SWEATING; TIME TO TREATMENT; TREMOR; VITAL SIGN; VOMITING; WEIGHT GAIN; BIPOLAR DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MONITORING; PSYCHOLOGY; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CHLORPROMAZINE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MONITORING; FEMALE; HUMANS; LITHIUM; MALE; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 84955445673     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2015.09.009     Document Type: Article

References (40)

1. Addoniozio G. Rapid induction of extrapyramidal side effects with combined use of lithium and neurolpetics. J Clin Psychopharmacol 1985;5:296-8.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fourth Edition, Washington, DC: American Psychiatric Association; 1994.
3. American Psychiatric Association. Global assessment of functioning scale. Diagnostic and statistical manual of mental disorders, Fourth Edition, Washington, DC: American Psychiatric Association; 1994.
4. Andreasen NC. Scale for the assessment of negative symptoms (SANS). Iowa City, IA: University of Iowa; 1984.
5. Andreasen NC. Scale for the assessment of positive symptoms (SAPS). Iowa City, IA: University of Iowa; 1984.
6. Berk M, Conus P, Lucas N, Hallam K, Malhi G, Dodd S, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord 2007;9(7):671-8.
7. Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J Affect Disord 2007; 100(1-3):279-81.
8. Cannon-Spoor EH, Potkin SG. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 1982;8:470-84.
9. Conus P, Berk M, McGorry PD. Pharmacological treatment in the early phase of bipolar disorders: what stage are we at? Aust N Z J Psychiatry 2006;40: 199-207.
10. First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for the diagnostic and statistical manual for mental disorders, Fourth Edition, Patient version, Washington, DC: American Psychiatric Press; 1997.
11. Gentile S. Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights. CNS Drugs 2007;21(5):367-87.
12. Gentile S. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. J Clin Psychopharmacol 2007;27(1): 35-45.
13. Guy W. ECDEU assessment manual for psychopharmacology. Rockville MD: National Institute of Mental Health; 1976 [DHEW Pub. No. (ADM) 76-338].
14. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007;21(11):911-36.
15. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
16. Heinrichs D, Hanlon T. The Quality of Life Scale: an instrument for rating the schizophrenia deficit syndrome. Schizophr Bull 1984;10:388-98.
17. Hetrick SE, Parker AG, Hickie IB, Purcell R, Yung AR, McGorry PD. Early identification and intervention in depressive disorders: towards a clinical staging model. Psychother Psychosom 2008;77(5):263-70.
18. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Random-ized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87.
19. Kahn R, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371: 1085-97.
20. Kane JM. Tardive dyskinesia in affective disorders. J Clinical Psychiatry 1999;60(Suppl. 5):43-7.
21. Ketter TA, Houston JP, Adams DH, Risser RC, Meyers AL, Williamson DJ, et al. Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar disorder based on number of previous manic or mixed episodes. J Clin Psychiatry 2006;67(1):95-101.
22. Kukopoulos A, Reginladi D, Laddomana P. Course of the manix-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol 1980;13:156-7.
23. Lieberman JA, Stroup S, McEvoy J, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
24. Liebermann JA. Comparative effectiveness of antipsychotic drugs. Arch Gen Psychiatry 2006;63:1069-72.
25. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
26. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective intervention. Aust N Z J Psychiatry 2006;40:616-22.
27. McGorry PD, Kilackey E, Yung AR. Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages. Med J Aust 2007;187(Suppl.):8-10.
28. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse 1998;9: 199-213.
29. National Early Psychosis Project Clinical Guidelines Working Party. Australian clinical guidelines for early psychosis. Melbourne: University of Melbourne; 1998.
30. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
31. Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, et al. Cognitivebehavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry 2006;188:313-20.
32. Simonsen E, Friis S, Haahr U, Johannessen JO, Larsen TK, Melle I, et al. Clinical epidemiologic first-episode psychosis: 1-year outcome and predictors. Acta Psychiatr Scand 2007;116:54-61.
33. Spearing MK, Post PM. Modification of the Clinical Global Impressions (CGI) Scales for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73: 159-71.
34. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in mania. Am J Psychiatry 1999;156:1264-6.
35. Thase ME, Denko T. Pharmacotherapy of mood disorders. Ann Rev Clin Psychol 2008;4:53-91.
36. Tohen M, Goldberg JF, Gonzales-Pinto AM, Azorin JM, Vieta E, Hardy-Bayle MC, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-26.
37. Tohen M, Golddberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;17: 227-37.
38. Wunderink L, Sytema S, Nienhuis FJ, Wiersma D. Clinical recovery in firstepisode psychosis. Schizophr Bull Mar 2009 2009;35(2):362-9 [Epub 2008 Nov 5].
39. Young RC, Biggs JT. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35.
40. Zarate CA, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004;161:169-71.